Simacort Drug Interactions

Acetylcholinesterase inhibitors: Triamcinolone may enhance the adverse/toxic effect of acetylcholinesterase inhibitors. Increased muscular weakness may occur. Monitor therapy.
Aldesleukin: Triamcinolone may diminish the neoplastic effect of aldesleukin. Avoid combination.
Aminoglutethimide: May increase the metabolism of Triamcinolone. Monitor therapy.
Amphotericin B: Triamcinolone may enhance the hypokalemic effect of amphotericin B. Monitor therapy.
Androgens: Triamcinolone may enhance the fluid-retaining effect of androgens. Monitor therapy.
Antidiabetic agents: Hyperglycemia-associated agents may diminish the therapeutic effect of antidiabetic agents. Monitor therapy.
Aprepitant: May increase the serum concentration of Triamcinolone. Consider therapy modification.
BCG: Triamcinolone may diminish the therapeutic effect of BCG. Avoid combination.
Calcitriol: Triamcinolone may diminish the therapeutic effect of calcitriol. Monitor therapy.
Ceritinib: Triamcinolone may enhance the hyperglycemic effect of ceritinib. Monitor therapy.
Coccidioides immitis skin test: Triamcinolone may diminish the diagnostic effect of Coccidioides immitis skin test. Monitor therapy.
Corticorelin: Triamcinolone may diminish the therapeutic effect of corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent of Triamcinolone therapy. Monitor therapy.
CYP3A4 inducers (strong): May decrease the serum concentration of Triamcinolone. Monitor therapy.
CYP3A4 inhibitors (strong): May increase the serum concentration of Triamcinolone. Monitor therapy.
Deferasirox: Triamcinolone may enhance the adverse/toxic effect of desferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Monitor therapy.
Denosumab: May enhance the adverse/toxic effect of Triamcinolone. Specifically, the risk for serious infections may be increased. Monitor therapy.
Echinacea: May diminish the therapeutic effect of Triamcinolone. Consider therapy modification.
Estrogen derivatives: May increase the serum concentration of Triamcinolone. Monitor therapy.
Fosaprepitant: May increase the serum concentration of Triamcinolone. The active metabolite aprepitant is likely responsible for this effect. Consider therapy modification.
Hyaluronidase: Triamcinolone may diminish the therapeutic effect of hyaluronidase. Patients receiving Triamcinolone (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification.
Indacaterol: May enhance the hypokalemic effect of Triamcinolone. Monitor therapy.
Isoniazid: Triamcinolone may decrease the serum concentration of isoniazid. Monitor therapy.
Leflunomide: Triamcinolone may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider not using a leflunomide loading dose in patients receiving Triamcinolone. Patients receiving both leflunomide and Triamcinolone should be monitored for bone marrow suppression at least monthly. Consider therapy modification.
Loxapine: Triamcinolone may enhance the adverse/toxic effect of loxapine. More specifically, the use of Triamcinolone to treat airway disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Avoid combination.
Mifepristone: May diminish the therapeutic effect of Triamcinolone. Mifepristone may increase the serum concentration of Triamcinolone. Avoid mifepristone in patients who require long-term Triamcinolone treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Triamcinolone effects may be reduced by mifepristone treatment. Avoid combination.
Mitotane: May decrease the serum concentration of Triamcinolone. Consider therapy modification.
Natalizumab: Triamcinolone may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Avoid combination.
Neuromuscular blocking agents (nondepolarizing): May enhance the adverse neuromuscular effect of Triamcinolone. Increased muscle weakness, possibly progressing to polyneuropathies and myopathies may occur. Consider therapy modification.
Nicorandil: Triamcinolone may enhance the adverse/toxic effect of nicorandil. Gastrointestinal perforation has been reported in association with this combination. Monitor therapy.
NSAIDs: Triamcinolone may enhance the adverse/toxic effect of NSAIDs. Monitor therapy.
Pimecrolimus: May enhance the adverse/toxic effect of Triamcinolone. Avoid combination.
Quinolone antibiotics: Triamcinolone may enhance the adverse/toxic effect of quinolone antibiotics. Specifically, the risk of tendonitis and tendon rupture may be increased. Monitor therapy.
Ritonavir: May enhance the adverse/toxic effect of Triamcinolone. Specifically, risks of developing iatrogenic Cushing syndrome and secondary adrenal insufficiency may be increased. Ritonavir may increase the serum concentration of Triamcinolone. Monitor therapy.
Roflumilast: May enhance the immunosuppressive effect of Triamcinolone. Consider therapy modification.
Salicylates: May enhance the adverse/toxic effect of Triamcinolone. This specifically includes gastrointestinal ulceration and bleeding. Triamcinolone may decrease the serum concentration of salicylates. Withdrawal of Triamcinolone may result in salicylate toxicity. Monitor therapy.
Sipuleucel-T: Triamcinolone may diminish the therapeutic effect of sipuleucel-T. Monitor therapy.
Tacrolimus (topical): May enhance the adverse/toxic effect of Triamcinolone. Avoid combination.
Telaprevir: Triamcinolone may decrease the serum concentration of telaprevir. Telaprevir may increase the serum concentration of Triamcinolone. Concurrent use of telaprevir and Triamcinolone is not recommended. When possible, consider alternatives. If used together, employ extra caution and monitor closely for excessive Triamcinolone effects and diminished telaprevir effects. Consider therapy modification.
Thiazide diuretics: Triamcinolone may enhance the hypokalemic effect of thiazide diuretics. Monitor therapy.
Tofacitinib: Triamcinolone may enhance the immunosuppressive effect of tofacitinib. Concurrent use with antirheumatic doses of methotrexate or non-biologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants. Avoid combination.
Trastuzumab: May enhance the neutropenic effect of Triamcinolone. Monitor therapy.
Urea cycle disorder agents: Triamcinolone may diminish the therapeutic effect of urea cycle disorder agents. More specifically, Triamcinolone may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of urea cycle disorder agents needed to maintain these concentrations in the target range. Monitor therapy.
Vaccines (inactivated): Triamcinolone may diminish the therapeutic effect of vaccines (inactivated).
Vaccines (live): Triamcinolone may enhance the adverse/toxic effect of vaccines (live). Triamcinolone may diminish the therapeutic effect of vaccines.
Warfarin: Triamcinolone may enhance the anticoagulant effect of warfarin. Monitor therapy.